Core Viewpoint - The National Healthcare Security Administration (NHSA) has intensified efforts to combat the illegal trade of "returned drugs," leading to a significant reduction in their availability in pharmacies and online platforms [1][8][10]. Group 1: Regulatory Actions - The NHSA has launched a comprehensive crackdown on the resale of returned drugs, with over 50 articles published on this issue in the past year [1]. - The implementation of a collaborative enforcement mechanism involving multiple departments, including public security and market regulation, marks a significant advancement in combating the issue [10]. - The introduction of a new monitoring module in the unified healthcare information platform allows for real-time tracking of returned drugs, involving both insured individuals and healthcare providers in the regulatory loop [10]. Group 2: Market Response - Many pharmacy owners are now avoiding returned drugs due to heightened penalties and the fear of criminal charges, resulting in a noticeable decrease in their presence in both physical and online pharmacies [8][10]. - Despite the crackdown, some intermediaries continue to exploit loopholes, particularly in private social networks, where advertisements for drug buybacks are still prevalent [11][14]. Group 3: E-commerce Challenges - E-commerce platforms remain a significant area for the sale of returned drugs, with complaints still being reported despite a reduction in overall incidents [18]. - The lack of pre-transaction scrutiny on e-commerce platforms makes it challenging to identify and prevent the sale of returned drugs, as the platforms primarily focus on compliance with seller qualifications rather than the actual products sold [18][20]. Group 4: Legal Implications - The legal framework surrounding the resale of returned drugs is becoming clearer, with potential criminal charges for those involved in fraudulent activities related to healthcare funds [20][23]. - Consumers who purchase returned drugs can pursue legal action for compensation, with specific pathways outlined for cases involving defective or returned drugs [24][26].

Core Viewpoint - The article emphasizes the importance of combating the illegal trade of "recycled drugs" to ensure public health and safety, highlighting the government's commitment to innovative regulatory measures to trace drug origins and prevent fraud [1][2]. Group 1: Regulatory Measures - The National Medical Insurance Administration has launched a special action to combat the illegal sale of recycled drugs, showcasing the effectiveness of "code-based supervision" [1]. - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box, allowing for traceable drug origins and destinations [1]. Group 2: Risks of Recycled Drugs - Recycled drugs are often sourced through illegal channels, repackaged, or have their information altered, posing significant health risks to patients and disrupting market order [1]. - The methods used by drug traffickers include enticing insured individuals to sell insurance-covered drugs for profit, falsifying documents to disguise the origins of drugs, and neglecting proper storage conditions during the repackaging process [1]. Group 3: Collaborative Efforts - It is essential for pharmaceutical companies, medical institutions, and retail pharmacies to strictly manage drug sales and prevent drugs from entering informal channels [2]. - Public awareness and responsibility are crucial in preventing participation in the illegal trade of insurance-covered drugs, emphasizing that drug safety is a collective responsibility [2].

Core Viewpoint - The article emphasizes the importance of combating the illegal trade of "recycled drugs" to ensure public health and safety, highlighting the government's commitment to innovative regulatory measures to trace and monitor drug sales [2][3]. Group 1: Definition and Risks of Recycled Drugs - Recycled drugs refer to pharmaceuticals that are illegally collected, repackaged, or have their information altered before being resold, often lacking proper regulatory oversight [2]. - These drugs pose significant health risks to patients and disrupt market order, as they are often sourced from dubious channels [2]. Group 2: Regulatory Measures - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code on each box of drugs sold, enhancing the ability to track drug origins and movements [2]. - This initiative aims to expose and eliminate the illegal practices associated with recycled drugs and related insurance fraud [2]. Group 3: Collaborative Efforts Required - A comprehensive approach is necessary to eradicate the illegal drug trade, involving strict management of drug sales by pharmaceutical companies, medical institutions, and retail pharmacies [3]. - Public awareness and responsibility are crucial, as individuals must refrain from participating in the illegal sale of medical insurance drugs [3].